NCT03190278View on ClinicalTrials.gov

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

December 24, 2024

Study Completion Date

December 31, 2025

Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
BIOLOGICAL

UCART123v1.2

Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor Biological/vaccine: CLLS52 A monoclonal antibody that recognizes the CD52 antigen Other Names: Alemtuzumab

Trial Locations (8)

10021

Weill Medical College of Cornell University, New York

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania - Abramson Cancer Center, Philadelphia

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

60201

Northwestern University, Chicago

77030

MD Anderson Cancer Center, Houston

94143

University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Cellectis S.A.
All Listed Sponsors
lead

Cellectis S.A.

INDUSTRY

NCT03190278 - Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter